StemRIM
Not an earnings-related IR material as the formal title is unknown
Clinical trial速報 for regenerative medicine Redasemide targeting epidermolysis bullosa with nutritional impairment and acute phase stroke. In the additional Phase 2 trial, closure of difficult ulcers achieved in 3/4 cases; in the global late Phase 2, primary endpoints not met, but efficacy trend and good tolerability observed. Future development plans to be pursued by Shionogi & Co., Ltd.
Key Figures
- 重要数値1: 不明（主要評価項目の達成状況は記載だが具体数値は不明）
- 重要数値2: 4例中3例達成（栄養障害型表皮水疱症 第2相追加試験）
- 重要数値3: 90日時点のmRSで有意差なし（急性期脳梗塞 グローバル後期第2相）
AI要約
Section Heading
This document is an IR report that速報 results of regenerative誘導医薬®レダセムチドのclinical trials. It describes results from additional Phase 2 and global late Phase 2 trials targeting nutritional impairment epidermolysis bullosa and acute phase stroke, with safety deemed favorable. In the追加試験 for epidermolysis bullosa, the primary endpoint of refractory ulcer closure was achieved in three cases, with some improvement in systemic symptoms. In the late-stage trial for acute phase stroke, the primary endpoint was not met and the difference was not statistically significant, but there are trends toward improvement and good safety similar to domestic studies. A divestiture to Shionogi & Co., Ltd. is planned to guide future development strategy.
Second Section Heading
This report demonstrates ongoing R&D continuity, and going forward, development progress and analyses by Shionogi & Co., Ltd. will be used to evaluate expansion of indications for epidermolysis bullosa and acute phase stroke and clinical applications. No new safety concerns, and tolerability is judged favorable.
StemRIM
Company overview · Stock price · Financial data · All IR
